Jodi L. Koehler

Jodi L. Koehler

Auto-generated profile, based on publicly available information

Jodi L. Koehler

Medtronic, Inc. , Minneapolis , United States of America

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YYYuichiro Yano
Yuichiro Yano
PGPhilip Greenland
Philip Greenland
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
EDEmile G. Daoud
Emile G. Daoud
JKJodi L. Koehler
Jodi L. Koehler
PZPaul D. Ziegler
Paul D. Ziegler
New technologies are diffusing into medical practice swiftly. Hand-held devices such as smartphones can record short-duration (e.g., 1-minute) ECGs, but their effectiveness in identifying patients with paroxysmal atrial fibrillation (AF) is unknown. We used data from the TRENDS study, which included 370 patients (mean age 71 years, 71% men, CHADS2 score≥1 point: mean 2.3 points) who had no documentation of atrial tachycardia (AT)/AF or antiarrhythmic or anticoagulant drug use at baseline. All were subsequently newly diagnosed with AT/AF by a cardiac implantable electronic device (CIED) over one year of follow-up. Using a computer simulation approach (5,000 repetitions), we estimated the detection rate for paroxysmal AT/AF via daily snapshot ECG monitoring over various periods, with the probability of detection equal to the percent AT/AF burden on each day. The estimated AT/AF detection rates with snapshot monitoring periods of 14, 28, 56, 112, and 365 days were 10%, 15%, 21%, 28%, and 50% respectively. The detection rate over 365 days of monitoring was higher in those with CHADS2 scores ≥2 than in those with CHADS2 scores of 1 (53% vs. 38%), and was higher in those with AT/AF burden ≥0.044 hours/day compared to those with AT/AF burden <0.044 hours/day (91% vs. 14%; both P<0.05). Daily snapshot ECG monitoring over 365 days detects half of patients who developed AT/AF as detected by CIED, and shorter intervals of monitoring detected fewer AT/AF patients. The detection rate was associated with individual CHADS2 score and AT/AF burden. ClinicalTrials.gov NCT00279981

31 July 2011 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
PDF file
SSShantanu Sarkar
Shantanu Sarkar
DHDouglas A. Hettrick
Douglas A. Hettrick
JKJodi Koehler
Jodi Koehler
TRTyson Rogers
Tyson Rogers
YGYanina Grinberg
Yanina Grinberg
WTW.H. Wilson Tang
W.H. Wilson Tang

5 February 2014 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
PZPaul D. Ziegler
Paul D. Ziegler
SSScott Sakaguchi
Scott Sakaguchi
GSGrant R. Simons
Grant R. Simons
JKJodi L. Koehler
Jodi L. Koehler
EWEduardo Warman
Eduardo Warman

5 April 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SSShantanu Sarkar
Shantanu Sarkar
JKJodi Koehler
Jodi Koehler
NVNeethu Vasudevan
Neethu Vasudevan
Background: Ambulatory risk stratification for worsening heart failure (HF) using diagnostics measured by insertable cardiac monitors (ICM) may depend on the left ventricular ejection fraction (LVEF). We evaluated risk stratification performance in patients with reduced versus preserved LVEF. Methods: ICM patients with a history of HF events (HFEs) were included from the Optum® de-identified Electronic Health Record dataset merged with ICM device-collected data during 2007–2021. ICM measures nighttime heart rate (NHR), heart rate variability (HRV), atrial fibrillation (AF) burden, rate during AF, and activity duration (ACT) daily. Each diagnostic was categorized into high, medium, or low risk using previously defined features. HFEs were HF-related inpatient, observation unit, or emergency department stays with IV diuresis administration. Patients were divided into two cohorts: LVEF ≤ 40% and LVEF > 40%. A marginal Cox proportional hazards model compared HFEs for different risk groups. Results: A total of 1020 ICM patients with 18,383 follow-up months and 301 months with HFEs (1.6%) were included. Monthly evaluations with a high risk were 2.3, 4.2, 5.0, and 4.5 times (p < 0.001 for all) more likely to have HFEs in the next 30 days compared to those with a low risk for AF, ACT, NHR, and HRV, respectively. HFE rates were higher for patients with LVEF > 40% compared to LVEF ≤ 40% (2.0% vs. 1.3%), and the relative risk between high-risk and low-risk for each diagnostic parameter was higher for patients with LVEF ≤ 40%. Conclusions: Diagnostics measured by ICM identified patients at risk for impending HFEs. Patients with preserved LVEF showed a higher absolute risk, and the relative risk between risk groups was higher in patients with reduced LVEF.

1 April 2014 in JACC
Verified
Journal Article
Closed access
YYYuichiro Yano
Yuichiro Yano
PGPhilip Greenland
Philip Greenland
DLDonald Lloyd-Jones
Donald Lloyd-Jones
EDEmile Daoud
Emile Daoud
JKJodi Koehler
Jodi Koehler
PZPaul Ziegler
Paul Ziegler

24 May 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
MDM Deus
M Deus
GRG Rajagopal
G Rajagopal
SSShantanu Sarkar
Shantanu Sarkar
SLS Landman
S Landman
JKJ Koehler
J Koehler
Background: The QT interval serves as a surrogate biomarker for ventricular repolarization. Variance in QT intervals can clinically lead to pro-arrhythmia and sudden cardiac death. An insertable cardiac monitor (ICM) device capable of continuously monitoring the QT interval over a long period can provide diagnostic value for evaluating physiologic or drug induced variations in QT interval. Objective: To analyze feasibility of continuous QTc interval monitoring in patients with ICM and evaluate the QTc interval changes in patients taking antiarrhythmic drugs. Methods: Patients QT intervals detected from daily ICM ECG data from real-world patients taking antiarrhythmic drugs such as sotalol, amiodarone and dofetilide during hospitalization while implanted with ICM were analyzed from the de-identified Electronic Health Record (EHR) database linked with ICM device data warehouse. The ICM ECG was processed through the previously defined QT detection algorithm which calculates the QTc interval for every beat to generate continuous long term QTc trends. A patient contributed to the prescription group if they were prescribed antiarrhythmics drugs prior to hospitalization in the EHR database otherwise they contributed to the non-prescription group. Patients from the prescription group who were administered antiarrhythmic drugs via injection or IV during hospitalization were removed from the analysis. A 30-day median QTc interval from 30-60 days prior to hospitalization was used as baseline. Wilcoxon signed-rank test was used to compare the paired difference from days 1-5, 1-10, 30-60, and 60-90 after hospitalization to their respective baseline. Results: 441 patients (avg. age: 70±11, 50.5% female) were included with 220 prescription and 221 non-prescription. The baseline QTc intervals were 414 and 417.3 msec for non-prescription and prescription groups, respectively. There was a significant increase in QTc on days 1-5, 1-10, 30-60, and 60-90 after hospital admission compared to the baseline (all p < 0.001) for the non-prescription group. The prescription group showed increase in QTc only on days 30-60 after hospitalization when compared to baseline (p<0.05). A larger QTc increase was observed in non-prescription receiving anti-arrhythmic loading on days 1-5 after hospitalization compared to patients on prescription prior to hospitalization (P<0.05). Conclusion: Utilizing a QT interval detection algorithm from an ICM can provide long term QT trends for patients with an ICM. Continuous monitoring of QT can help to detect sudden changes in QT due to antiarrhythmic drugs which may lead to increased risk of arrhythmias or cardiac arrest.